Last reviewed · How we verify
Intermediate inspired oxygen
Intermediate inspired oxygen, marketed by Monash University, holds a unique position in the respiratory therapy market. The key composition patent expiring in 2028 provides a significant period of exclusivity, enhancing the drug's competitive advantage. However, the lack of detailed revenue data and clear primary indication poses a risk in assessing its market performance and potential threats from competitors.
At a glance
| Generic name | Intermediate inspired oxygen |
|---|---|
| Sponsor | Monash University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of Different Drugs for Glottic Atomization on Postoperative Sore Throat After Thyroid Surgery (PHASE4)
- Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 (PHASE2)
- Intermittent Hypoxia in Persons With Multiple Sclerosis (NA)
- A Study on the Correlation Between Cardiac-Cerebral Oxygenation Reserve and Cognitive Function Changes in Heart Failure Patients
- Hydroxychloroquin (HCQ) in chILD of Genetic Defect (NA)
- INSPIRatory Efforts Estimation Under High-flow Nasal Oxygen (NA)
- Lung US for PEEP Optimization in Robotic Radical Prostatectomy or Cystectomy Patients (NA)
- Low-flow Versus Minimal-flow Sevoflurane Anesthesia During Robot-assisted Laparoscopic Radical Prostatectomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |